Literature DB >> 10520004

Prognostic evaluation in multiple myeloma: an analysis of the impact of new prognostic factors.

I Turesson1, N Abildgaard, T Ahlgren, I Dahl, E Holmberg, M Hjorth, J L Nielsen, A Odén, C Seidel, A Waage, J Westin, F Wislöff.   

Abstract

We have analysed the prognostic information for survival of presenting features in an unselected series of 394 myeloma patients. 15 variables with significant prognostic information were identified, among these were some not previously or only recently reported: serum levels of hepatocyte growth factor (HGF), interleukin-6 (IL-6), C-terminal cross-linked telopeptide of collagen I (ICTP) and soluble interleukin-6 receptor (sIL-6R). In a multivariate Cox analysis six variables were significantly and independently associated with poor survival: high age, low W.H.O.-performance status (PS), high serum levels of calcium, beta-2-microglobulin (beta-2M), IL-6 and sIL-6R. A risk score formed to predict survival for each percentile of the patient population allowed an efficient separation of prognostic groups. The discriminating power of the model compared favourably with three other previously published staging systems applied to the study population. Exclusion of IL-6 and sIL-6R from the model only marginally decreased the efficacy of the separation. The predictive value of some variables (sIL-6R, beta-2M and W.H.O.-PS) decreased significantly over time. We conclude that formation of a risk score based on independent variables is an efficient way to separate prognostic groups, that the contribution of new and not easily available parameters should be thoroughly evaluated before inclusion in prognostic models for clinical use and that the predictive value of parameters may decrease over time.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10520004     DOI: 10.1046/j.1365-2141.1999.01651.x

Source DB:  PubMed          Journal:  Br J Haematol        ISSN: 0007-1048            Impact factor:   6.998


  12 in total

1.  Analysis of Real-World Data on Overall Survival in Multiple Myeloma Patients With ≥3 Prior Lines of Therapy Including a Proteasome Inhibitor (PI) and an Immunomodulatory Drug (IMiD), or Double Refractory to a PI and an IMiD.

Authors:  Saad Usmani; Tahamtan Ahmadi; Yvette Ng; Annette Lam; Avinash Desai; Ravi Potluri; Maneesha Mehra
Journal:  Oncologist       Date:  2016-08-02

2.  Exposure-Response and Tumor Growth Inhibition Analyses of the Monovalent Anti-c-MET Antibody Onartuzumab (MetMAb) in the Second- and Third-Line Non-Small Cell Lung Cancer.

Authors:  Kelong Han; Pascal Chanu; Fredrik Jonsson; Helen Winter; René Bruno; Jin Jin; Mark Stroh
Journal:  AAPS J       Date:  2016-12-27       Impact factor: 4.009

3.  Lenalidomide in multiple myeloma: an evidence-based review of its role in therapy.

Authors:  Paul Richardson; Constantine Mitsiades; Jacob Laubach; Robert Schlossman; Irene Ghobrial; Teru Hideshima; Nikhil Munshi; Kenneth Anderson
Journal:  Core Evid       Date:  2010-06-15

4.  Targeting executioner procaspase-3 with the procaspase-activating compound B-PAC-1 induces apoptosis in multiple myeloma cells.

Authors:  Shadia Zaman; Rui Wang; Varsha Gandhi
Journal:  Exp Hematol       Date:  2015-08-06       Impact factor: 3.084

5.  Targeting MET transcription as a therapeutic strategy in multiple myeloma.

Authors:  Cornel J Phillip; Christine M Stellrecht; Ramadevi Nimmanapalli; Varsha Gandhi
Journal:  Cancer Chemother Pharmacol       Date:  2008-05-29       Impact factor: 3.333

6.  [Staging of multiple myeloma with MRI: comparison to MSCT and conventional radiography].

Authors:  A Baur-Melnyk; M Reiser
Journal:  Radiologe       Date:  2004-09       Impact factor: 0.635

7.  Long-term outcome of patients with multiple myeloma after autologous hematopoietic cell transplantation and nonmyeloablative allografting.

Authors:  Marcello Rotta; Barry E Storer; Firoozeh Sahebi; Judith A Shizuru; Benedetto Bruno; Thoralf Lange; Edward D Agura; Peter A McSweeney; Michael A Pulsipher; Parameswaran Hari; Richard T Maziarz; Thomas R Chauncey; Frederick R Appelbaum; Mohamed L Sorror; William Bensinger; Brenda M Sandmaier; Rainer F Storb; David G Maloney
Journal:  Blood       Date:  2008-11-17       Impact factor: 22.113

8.  Targeting the pro-survival protein MET with tivantinib (ARQ 197) inhibits growth of multiple myeloma cells.

Authors:  Shadia Zaman; Shujun Shentu; Jing Yang; Jin He; Robert Z Orlowski; Christine M Stellrecht; Varsha Gandhi
Journal:  Neoplasia       Date:  2015-03       Impact factor: 5.715

9.  Phase II study of the c-MET inhibitor tivantinib (ARQ 197) in patients with relapsed or relapsed/refractory multiple myeloma.

Authors:  Muhamed Baljevic; Shadia Zaman; Veerabhadran Baladandayuthapani; Yan Heather Lin; Claudia Morales de Partovi; Zuzana Berkova; Behrang Amini; Sheeba K Thomas; Jatin J Shah; Donna M Weber; Min Fu; Charles S Cleeland; Xin Shelley Wang; Christine M Stellrecht; Richard E Davis; Varsha Gandhi; Robert Z Orlowski
Journal:  Ann Hematol       Date:  2017-03-23       Impact factor: 3.673

10.  Serum B-cell maturation antigen: a novel biomarker to predict outcomes for multiple myeloma patients.

Authors:  Michael Ghermezi; Mingjie Li; Suzie Vardanyan; Nika Manik Harutyunyan; Jillian Gottlieb; Ariana Berenson; Tanya M Spektor; Claudia Andreu-Vieyra; Sophia Petraki; Eric Sanchez; Kyle Udd; Cathy S Wang; Regina A Swift; Haiming Chen; James R Berenson
Journal:  Haematologica       Date:  2016-12-29       Impact factor: 9.941

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.